- $180.81m
- $20.73m
- $53.43m
U.S. STOCKS ON THE MOVE-Netflix, ServiceNow, D.R. Horton
Invivyd to launch antibody trial for long COVID, vaccine‑linked conditions; shares fall
U.S. STOCKS ON THE MOVE-Invivyd, US natgas companies, New Era Energy
U.S. STOCKS ON THE MOVE-Invivyd, US natgas companies, New Era Energy
Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody
Brief: Invivyd Announces Initiation Of DECLARATION Clinical Trial, A Phase 3 Placebo-Controlled Pivotal Study Of VYD2311, A Vaccine-Alternative Antibody To Prevent Covid
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials
Invivyd rises after unveiling promising new antibody for children
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Energizer Holdings, Target
U.S. STOCKS ON THE MOVE-Ardent Health, Intuit, Galmed Pharma
U.S. STOCKS ON THE MOVE-Cloudflare, Legence, Lumentum
Biopharma co Invivyd tumbles on $125 mln stock sale
Brief: Invivyd Prices 44 Million Shares At $2.50 Each
Invivyd Q3 net loss beats estimates on higher PEMGARDA sales among healthcare providers
Brief: Invivyd Q3 EPS USD -0.06
Brief: Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311
Brief: Invivyd Appoints Paul B. Bolno, M.D. To Its Board Of Directors